期刊
DEVELOPMENTAL NEUROBIOLOGY
卷 79, 期 7, 页码 750-766出版社
WILEY
DOI: 10.1002/dneu.22713
关键词
Alzheimer's disease; amyloid; Down syndrome; neuropathology; positron emission tomography; striatum
资金
- National Institute on Aging [P01AG014449, P01AG025204, R01AG052528, R01AG061566, U01AG051406]
Down syndrome (DS) results in an overproduction of amyloid-beta (A beta) peptide associated with early onset of Alzheimer's disease (AD). DS cases have A beta deposits detectable histologically as young as 12-30 years of age, primarily in the form of diffuse plaques, the type of early amyloid pathology also seen at pre-clinical (i.e., pathological aging) and prodromal stages of sporadic late onset AD. In DS subjects aged >40 years, levels of cortical A beta deposition are similar to those observed in late onset AD and in addition to diffuse plaques involve cored plaques associated with dystrophic neurites (neuritic plaques), which are of neuropathological diagnostic significance in AD. The purpose of this review is to summarize and discuss findings from amyloid PET imaging studies of DS in reference to postmortem amyloid-based neuropathology. PET neuroimaging applied to subjects with DS has the potential to (a) track the natural progression of brain pathology, including the earliest stages of amyloid accumulation, and (b) determine whether amyloid PET biomarkers predict the onset of dementia. In addition, the question that is still incompletely understood and relevant to both applications is the ability of amyloid PET to detect A beta deposits in their earliest form.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据